Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574208 | 0.88 | ALDH1A1 (0.43) | CES2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL13193210 | 0.85 | CES2 (0.46) | CES2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL25062278 | 0.84 | MEN1 (0.33) | ALDH1A1TSHRMEN1KMT2ATDP1 | |
| SCHEMBL23703846 | 0.83 | MEN1 (0.34) | MEN1KMT2ATDP1 | |
| SCHEMBL5735758 | 0.82 | MEN1 (0.33) | TSHRMEN1KMT2ATDP1 | |
| SCHEMBL26383031 | 0.82 | ALDH1A1 (0.41) | CES2ALDH1A1TSHRNR1I2MEN1 | |
| SCHEMBL14076749 | 0.82 | ALDH1A1 (0.41) | CES2ALDH1A1TSHRNR1I2MEN1 | |
| SCHEMBL1254697 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1KMT2ATDP1 | |
| SCHEMBL25255150 | 0.81 | MEN1 (0.34) | ALDH1A1TSHRMEN1KMT2ATDP1 | |
| SCHEMBL29053225 | 0.80 | CHRNB2 (0.40) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238461-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | CES2 430/4885ALDH1A1 1381/4885TSHR 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.